One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood.v128.22.lba-5.lba-5
Copy DOI Journal: Blood |  Publication Date: Dec 2, 2016 |
 Citations: 30 |
Affiliation: Guy's and St Thomas' NHS Foundation Trust, Cleveland Clinic, Icahn School of Medicine at Mount Sinai, CTI BioPharma (United States), University of Szeged, Mayo Clinic, Northwestern University, The University of Texas MD Anderson Cancer Center, Michigan Center for Translational Pathology, University of Michigan–Ann Arbor, University of California, San Diego, Stanford University, Stanford Medicine, Beatson West of Scotland Cancer Centre, Princess Margaret Cancer Centre, University of TorontoResults of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
